A chemotherapy combined with an anti-angiogenic drug applied to a cancer model including angiogenesis
Authors:
- Christophe LetellierCLChristophe Letellier
- Sourav Kumar SasmalSSSourav Kumar Sasmal
- Clément DraghiCDClément Draghi
- Fabrice DenisFDFabrice Denis
- Dibakar GhoshDGDibakar Ghosh
- 1 June 2017
- journal article
- Published by Elsevier in Chaos, Solitons & Fractals
- Vol. 99, 297-311
Abstract
No abstract availableThis publication has 63 references indexed in Scilit:
- What can be learned from a chaotic cancer model?Journal of Theoretical Biology, 2013
- Mitosis-targeted anti-cancer therapies: where they standCell Death & Disease, 2012
- A mathematical model of combined bacillus Calmette-Guerin (BCG) and interleukin (IL)-2 immunotherapy of superficial bladder cancerJournal of Theoretical Biology, 2011
- Why don't we get more cancer? A proposed role of the microenvironment in restraining cancer progressionNature Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Cancer immunotherapy, mathematical modeling and optimal controlJournal of Theoretical Biology, 2007
- Role of Angiogenesis in Human Tumor Dormancy: Animal Models of the Angiogenic SwitchCell Cycle, 2006
- Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppressionNature Medicine, 1995
- Tumor Angiogenesis: Therapeutic ImplicationsNew England Journal of Medicine, 1971
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971